Review of 2025

2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform. Across our portfolio, we have maintained momentum in both animal health where progress in our canine study may provide translational insights relevant to future human applications as well as therapeutic development for dogs.

These advancements have been supported by a strengthened network of leading academic collaborators and laboratories. Together, with continued backing from international institutional investors and previously awarded government grants, this ecosystem helped accelerate Genflow's scientific and clinical development throughout 2025.

Program Highlights

We've made a number of notable strides across our programs this year, including:

Dog Aging (GF-1004)

We made significant strides in our clinical trial for aging dogs with full administration of our investigational SIRT6-based gene therapy now completed. No adverse events were reported during the dosing phase of the study, with no serious, moderate, or minor side effects observed. The study which began in March 2025, is being conducted as a blinded clinical trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers.

Dogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment planned at the six-month timepoint and results expected in June-July 2026 to evaluate durability and longer-term effects.

MASH (GF-1002)

Our MASH program saw good progress in 2025. While GLP-1 therapies have addressed early-stage MASH, patients with advanced fibrosis - roughly one-third of the population - still face limited treatment options. In response, we repositioned GF-1002 to target this high-need group, leveraging its antifibrotic properties and potential to prevent progression to cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the prevention of HCC.

We are now finalizing our IND package and evaluating mRNA/LNP delivery as an alternative to AAV, an approach that could enable repeat dosing and lower manufacturing costs. Encouraging data continue to support this next phase of research and development.

Glaucoma

In 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows promise in glaucoma, a leading cause of irreversible blindness. Current treatments primarily manage intraocular pressure but do little to prevent optic nerve degeneration. Our preclinical data suggest SIRT6 overexpression may protect retinal ganglion cells and preserve optic nerve function, shifting the focus from symptom control to true neuroprotection.

We are advancing discussions with a leading LNP partner to support delivery innovation in this space and are securing a full-service CRO to manage formulation through preclinical execution. With the global glaucoma market approaching USD $12-14 billion by the early 2030s, this represents a compelling long-term opportunity for us.

Additional Programs

We continued to advance our broader pipeline and are pleased with the steady advancement of the sarcopenia program, fully consistent with our development plans. In parallel, the ExoFastTrack initiative continues to move forward, generating important data that will support and accelerate several of our other development programs.

Looking Ahead to 2026

As we move into 2026, we do so with confidence, discipline, and a clear strategic focus. The coming year will emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest. Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain.

With multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies.

Thank you for your continued support and confidence in Genflow.

Eric Leire

Founder & Chief Executive Officer